Cellular or antibodies mediate the rejection of solid organ allotransplants. In the majority of cases, the rejection reaction is directly aimed at human leukocyte antigen (HLA) expressed on the cells of the transplanted organ. The detection of HLA antibodies, particularly those directly aimed at the HLA of the donor has been at the forefront of donor-recipient histocompatibility testing since transplantation became a clinical reality. Creative Biolabs provides a set of HLA antibody detection assays to assess an individual's sensitization status and identify the antigens specifically targeted by those antibodies.
Panel Reactive Antibody (PRA) Screening
HLA Single Antigen (SAB) Bead Assay
HLA Single Antigen-C1q Screening
Antibody Specificity Profile Assay
Complement-dependent Cytotoxic Crossmatch (CDC-XM)
Flow Cytometric Crossmatch (FCXM)
HLA antibody testing assesses can assess an individual's sensitization status and identifies the antigens specifically targeted by those antibodies. Panel reactive antibody screening is used to identify anti-HLA antibodies assess reactions of antibodies with purified or recombinant HLA antigens coupled to specialized microparticles. CDC-XM and FCXM are used to assess the reactivity of the patient's serum with a specific donor's antigens. Each of these assays has varying sensitivity and specificity for HLA antibody identification. Specific differences between these assays are shown in the following table:
Assay | Phase | Specificity | Sensitivity | Result |
Complement-dependent Cytotoxic Crossmatch | Cell Phase | IgG, Class I and Class II |
|
Positive or negative |
HLA Single Antigen-C1q Screening | Solid Phase | IgG, Class I and Class II | Positive HLA specificities | |
Flow Cytometric Crossmatch | Cell Phase | IgG, Class I and Class II | Median channel shift | |
Panel Reactive Antibody Screening | Solid Phase | IgG, Class I and Class II | %PRA and Positive HLA Specificities (HLA specificities can be identified up to 70% PRA) | |
HLA Single Antigen Bead Assay | Solid Phase | IgG, Class I and Class II | Positive HLA specificities and strength | |
Antibody Specificity Profile Assay | Solid Phase | IgG, Class I | Positive HLA specificities |
As a world leader in HLA testing, Creative Biolabs offers a collection of integrated solutions to help you identify HLA antibodies that may cause graft rejection. Our provided selection of HLA antibodies detection assays vary in format, sensitivity, and specificity and all products are designed for ease of use, lab efficiency, and optimized automation. If you are interested in our HLA antibody detection assay, please feel free to contact us directly.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION